ReviewAmerican journal of clinical pathology2026
Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.
Review in American journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
objectiveIdiopathic multicentric Castleman disease (iMCD) is a rare condition with a wide range of signs and symptoms that often overlap with other conditions that cause lymphadenopathy. The diagnosis of iMCD remains challenging, even among experts. Our aim is to highlight the heterogeneity of histopathologic features and presentations of iMCD and to provide tools to help diagnose and raise awareness of this rare condition.
methodsWe review the most relevant clinicopathologic aspects of iMCD and present our process to accurately diagnose this condition using a case-based approach. We describe how to incorporate the iMCD diagnostic criteria, including grading of histomorphology, laboratory, and clinical findings.
resultsHere, we describe our system to grade histopathologic features in iMCD. Together with radiologic findings and laboratory and clinical information, this system helps clinicians accurately identify iMCD and its subtypes, leading to more appropriate and timely diagnosis and treatment.
conclusionsThe diagnosis of iMCD can be challenging and requires a multidisciplinary team of hematologists, pathologists/hematopathologists, and other specialists. There is a pressing and unmet clinical need for a harmonized system to grade the histopathologic features of iMCD. This condition should be included in the differential diagnosis when other causes of a lymphoproliferative disorder (eg, infections, autoimmune/inflammatory disorders, malignancy) have been ruled out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.